Disclosures for "Congenital Contractures of the Limbs and Face, Hypotonia, and Developmental Delay (CLIFAHDD) Syndrome: Case Series and Systematic Review"
-
Dr. Garcia Velazquez has nothing to disclose.
-
Dr. Parra-Díaz has nothing to disclose.
-
Dr. Altintas has nothing to disclose.
-
Dr. Hadouiri has nothing to disclose.
-
Dr. Durham has received personal compensation in the range of $50,000-$99,999 for serving as a Director with The TBCK Foundation. Dr. Durham has received personal compensation in the range of $10,000-$49,999 for serving as a Manager with The Channeling Hope Foundation.
-
Mr. Martin has received personal compensation for serving as an employee of Roche Pharma AG. Mr. Martin has stock in Biotest AG. Mr. Martin has stock in Gilead Sciences. Mr. Martin has stock in Medtronic plc. Mr. Martin has stock in Roche Holding AG.
-
Dr. Monteil has nothing to disclose.
-
Dr. Gooch has nothing to disclose.
-
Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $0-$499 for serving as a Consultant for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix . The institution of Dr. Gil-Nagel has received research support from Jazz Pharmaceuticals. The institution of Dr. Gil-Nagel has received research support from PTC Therapeutics. The institution of Dr. Gil-Nagel has received research support from Zogenix. The institution of Dr. Gil-Nagel has received research support from Agencia Estatal Innovacion.
-
Dr. Calame has nothing to disclose.
-
An immediate family member of Dr. Tanner has received personal compensation for serving as an employee of Channeling Hope Foundation. The institution of Dr. Tanner has received research support from NIA, NINDS. Dr. Tanner has a non-compensated relationship as a Chief Scientific Officer with Channeling Hope Foundation that is relevant to AAN interests or activities.